Ampelopsin Inhibits Cell Viability and Metastasis in Renal Cell Carcinoma by Negatively Regulating the PI3K/AKT Signaling Pathway

Author:

Zhao Zhonghe1ORCID,Jiang Yan2ORCID,Liu Zhongguo3ORCID,Li Qingyan4ORCID,Gao Tiantian5ORCID,Zhang Shengxia6ORCID

Affiliation:

1. Department of Urology Surgery, Jiaozhou Central Hospital, Qingdao 266300, Shandong Province, China

2. Hemodialysis Room, The No. 4 People’s Hospital of Jinan, Jinan 250031, Shandong Province, China

3. Department of Urology Surgery, Affiliated Qingdao Central Hospital, Qingdao University, Qingdao 266000, Shandong Province, China

4. Department of Clinical Laboratory, Zhangqiu District People’s Hospital, Jinan 250200, Shandong Province, China

5. Department of Nephrology, Zhangqiu District People’s Hospital, Jinan 250200, Shandong Province, China

6. Department of Nephrology Geriatrics, The Third People’s Hospital of Qingdao, Qingdao 266041, Shandong Province, China

Abstract

Background. Previous studies have shown that Ampelopsin has an inhibitory effect on human tumors. However, the effect of Ampelopsin on renal cell carcinoma (RCC) is rarely reported. Therefore, this study aims to explain the role of Ampelopsin in RCC. Methods. Different concentrations of Ampelopsin (0, 10, 25, 50, and 100 μM) were used to treat 786-O cells. Cell viability was detected by MTT assay, colony formation assay, and flow cytometry assay. Transwell assay and Wound healing assay were used to detect cell migration and invasion. Western blot analysis was applied to detect protein expression. Results. Ampelopsin inhibited cell proliferation and induced apoptosis in RCC. And Ampelopsin can inhibit cell migration and invasion in RCC. All these results changed in a dose-dependent manner. Ampelopsin (100 uM) had the strongest inhibitory effect on cell viability and metastasis. In addition, Ampelopsin negatively regulated the PI3K/AKT signaling pathway in RCC cells. Moreover, Ampelopsin was only cytotoxic to RCC cells. Conclusion. Ampelopsin inhibits cell viability and metastasis in RCC by negatively regulating the PI3K/AKT signaling pathway.

Publisher

Hindawi Limited

Subject

Complementary and alternative medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3